JOURNAL ARTICLE

Report Summarizes Epilepsy Study Findings from Soochow University (Real-world Safety Profile of Fenfluramine In Refractory Epilepsy: a Pharmacovigilance Study Based On Faers Database).

  • Published In: Mental Health Weekly Digest, 2025. P. 4418 1 of 2

  • Database: Psychology Source 2 of 2

Abstract

The article focuses on a study evaluating the safety profile of Fenfluramine, a drug used for refractory epilepsy, through the FDA Adverse Event Reporting System (FAERS) database. Conducted by researchers from Soochow University in Jiangsu, People's Republic of China, the study analyzed 20,474,269 adverse event reports, identifying 2,612 cases associated with Fenfluramine. The findings highlighted that nervous system disorders were the most reported adverse events, along with notable concerns regarding pulmonary valve incompetence and newly identified psychiatric issues such as aggression and behavior disorders. The research underscores the importance of comprehensive risk assessment in clinical practice despite Fenfluramine's therapeutic benefits for epilepsy. [Extracted from the article]

Additional Information

  • Source:Mental Health Weekly Digest. 2025/10, p4418
  • Document Type:Article
  • Subject Area:Psychology
  • Publication Date:2025
  • ISSN:1543-6616
  • Accession Number:188416194
  • Copyright Statement:Copyright of Mental Health Weekly Digest is the property of NewsRx and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.